Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 7 2 2018 05 20 Beyond renoprotective impact; ameliorative effects of metformin on malignancies 50 54 10.15171/npj.2018.12 EN Nozar Dorestan Mohammad Bahadoram Mohammadreza Khosravi Sara Bahadoram Mohammad Davoodi Maedeh Barahman Journal Article 10.15171/npj.2018.12 2017 11 14 2018 02 20 Diabetes therapies were associated with either a reduced or increased risk of cancer. There are continuous discussions about a possible protective action of metformin. In fact, metformin, a commonly consumed anti-diabetic medication has an ameliorative impact on some cancers by direct (preventing cell growth and apoptosis) and indirect (increasing insulin sensitivity) effects. Observational reports have suggested which metformin reduces the incidence of few common cancers. In general, metformin is an extensively recommended anti-diabetic medication with a recognized ability coupled with a satisfactory and safety profile and inexpensive. This review article considers reduction and protective abilities of metformin on cancers especially prostate, liver, breast, lung, and colon cancer.